Labcorp EVP granted options and RSUs

Labcorp Holdings Inc. executive Akinbolade Oyegunwa reported new equity awards.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Labcorp Holdings Inc. executive Akinbolade Oyegunwa reported new equity awards. On 02/10/2026, the EVP, CIO & CTO acquired 2,400 non-qualified stock options with an exercise price of $284.5 per share under the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan.

The options vest in three equal annual installments beginning on 02/10/2026 and are exercisable until 02/09/2036. On the same date, Oyegunwa also received 810 Restricted Stock Units, each representing one share of common stock, which will vest in three equal annual installments beginning on February 10, 2027. Following this grant, Oyegunwa holds 2,420 Restricted Stock Units in total.

Insider Trade Summary

Grant/Award: 3,210 shares

Grant/Award 2 txns

Insider Oyegunwa Akinbolade

Role EVP, CIO & CTO

Type	Security	Shares	Price	Value
Grant/Award	Non-qualified Stock Options	2,400	$0.00	$0.00
Grant/Award	Restricted Stock Unit	810	$0.00	$0.00

Holdings After Transaction: Non-qualified Stock Options — 2,400 contracts (Direct); Restricted Stock Unit — 2,420 contracts (Direct)

Footnotes (5)

F1. Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan.
F2. The option vests in three equal annual installments beginning on the date reflected in this column.
F3. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
F4. The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027.
F5. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Labcorp (LH) report for Akinbolade Oyegunwa?

Labcorp reported that EVP, CIO & CTO Akinbolade Oyegunwa received equity awards on February 10, 2026. He was granted 2,400 non-qualified stock options and 810 Restricted Stock Units as part of his compensation package under the company’s 2025 Omnibus Incentive Plan.

How many stock options did Akinbolade Oyegunwa receive from Labcorp (LH)?

Akinbolade Oyegunwa received 2,400 non-qualified stock options on February 10, 2026. These options were granted under Labcorp Holdings Inc.’s 2025 Omnibus Incentive Plan and carry an exercise price of $284.5 per share, aligning his long-term incentives with shareholder value.

What is the vesting schedule for Oyegunwa’s Labcorp (LH) stock options?

The 2,400 non-qualified stock options granted to Akinbolade Oyegunwa vest in three equal annual installments. Vesting begins on February 10, 2026, and continues annually, with the options remaining exercisable until February 9, 2036, subject to the plan’s terms and conditions.

What Restricted Stock Units did Labcorp (LH) grant to Akinbolade Oyegunwa?

On February 10, 2026, Labcorp granted Akinbolade Oyegunwa 810 Restricted Stock Units. Each RSU represents the right to receive one share of Labcorp common stock, providing equity-based compensation that aligns his interests with long-term company performance and shareholder returns.

When do Akinbolade Oyegunwa’s Labcorp (LH) RSUs vest?

The 810 Restricted Stock Units awarded to Akinbolade Oyegunwa vest in three equal annual installments. Vesting starts on February 10, 2027, and continues annually, subject to continued service and the terms of Labcorp Holdings Inc.’s 2025 Omnibus Incentive Plan.

How many Labcorp (LH) Restricted Stock Units does Oyegunwa hold after this grant?

After the February 10, 2026 grant, Akinbolade Oyegunwa beneficially holds 2,420 Restricted Stock Units. This figure represents the aggregate number of Labcorp Holdings Inc. RSUs credited to him, each potentially settling in one share of common stock upon vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/12/2026 - 03:39 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Oyegunwa Akinbolade

(Last)

(First)

(Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON

27215

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, CIO & CTO

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-qualified Stock Options⁽¹⁾	$284.5	02/10/2026		A		2,400		02/10/2027⁽²⁾	02/09/2036	Common Stock	2,400	$0	2,400	D
Restricted Stock Unit	⁽³⁾	02/10/2026		A		810		⁽⁴⁾	⁽⁴⁾	Common Stock	810	$0	2,420⁽⁵⁾	D

Explanation of Responses:

1. Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan.

2. The option vests in three equal annual installments beginning on the date reflected in this column.

3. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

4. The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027.

5. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

	/s/ Kathryn W. Kyle, Attorney-in-Fact for Akinbolade Oyegunwa	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR